InMed Pharmaceuticals Inc. has launched B2B sales of delta-9-dominant tetrahydrocannabivarin (d9-THCV) into the health and wellness sector via its wholly-owned subsidiary, BayMedica LLC.

“We are very excited to launch our highly anticipated d9-THCV and further enhance BayMedica’s growing product portfolio,” said Shane Johnson, SVP and general manager of BayMedica. “THCV is one of the few rare cannabinoids that has been researched in early clinical trials for various therapeutic effects, fueling significant interest by end-product manufacturers and consumers alike. In anticipation of this launch, we have expanded internal sales and marketing infrastructure, developed new distribution channels and optimized the supply chain to ensure a consistent and reliable supply of a high quality product. As this market continues to mature, we are well positioned to be a leading supplier of rare cannabinoids to the health and wellness industry. We currently have several high-value, rare cannabinoids in various stages of commercial development and will continue to expand our cannabinoid portfolio over the coming years”.

Although similar in name and structure to its intoxicating cousin THC, THCV has a slightly modified structure that leads to significantly different physiological effects, including being non-intoxicating. In addition, while THC is found abundantly in many strains of the cannabis plant, THCV is a rare cannabinoid that is generally found in only trace amounts in the plant. 

D9-THCV has been researched for a variety of physiological benefits, most notably for its appetite suppressing effects, making it a compelling compound for use in weight management. It has also attracted interest for its potential ability to help maintain normal blood sugar levels and has been studied for myriad other effects.

InMed is committed to developing products based on scientific evidence, and as previously announced, BayMedica has supplied d9-THCV to be evaluated in Radicle Science’s “Radicle Energy” study on energy, focus/attention, appetite and weight/body mass index. The study is being conducted to provide valuable third party validation of the potential effects of d9-THCV.

BayMedica manufactures a d9-THCV to high purity via a proprietary process. BayMedica’s cannabinoids are made in accordance with food-grade GMP standards and are rigorously tested at certified laboratories. Like all BayMedica minor cannabinoid products, d9-THCV can be combined in precise ratios with other cannabinoids to create unique health and wellness products.

Want more legal cannabis market news and information?
Join Cannabis Products on Facebook, Twitter, YouTube, and LinkedIn today!